CGC Stock Overview
Engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Canopy Growth Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.19 |
| 52 Week High | CA$14.92 |
| 52 Week Low | CA$0.77 |
| Beta | 2.19 |
| 1 Month Change | 5.31% |
| 3 Month Change | -45.41% |
| 1 Year Change | -84.99% |
| 3 Year Change | -97.86% |
| 5 Year Change | -99.24% |
| Change since IPO | -96.39% |
Recent News & Updates
Cannabis Investors Should Sell Canopy Growth
Mar 30Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak
Feb 17Recent updates
Cannabis Investors Should Sell Canopy Growth
Mar 30Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak
Feb 17Canopy Growth: Still A Disaster Heading Into Fiscal Q3 Results
Feb 06Crashing Canopy Growth Is Still Not A Buy
Jan 22Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty
Jan 11Avoid Canopy Growth
Nov 10Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges
Oct 05Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High
Aug 27Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)
Jun 17Canopy Growth: Another Ugly Cannabis Report
Jun 03Canopy Growth Set For U.S. Cannabis Markets
Apr 26Canopy Growth Is Climbing, But It Won't Last
Mar 22Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come
Feb 06Canopy Growth: Further Implosion Is Now A Matter Of When Not If
Jan 29Avoid Canopy Growth After Failed Equity Sale
Jan 14Shareholder Returns
| CGC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 26.6% | 6.6% | -1.1% |
| 1Y | -85.0% | -1.1% | 5.9% |
Return vs Industry: CGC underperformed the US Pharmaceuticals industry which returned -2.2% over the past year.
Return vs Market: CGC underperformed the US Market which returned 5.7% over the past year.
Price Volatility
| CGC volatility | |
|---|---|
| CGC Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CGC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CGC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,029 | Luc Mongeau | www.canopygrowth.com |
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices.
Canopy Growth Corporation Fundamentals Summary
| CGC fundamental statistics | |
|---|---|
| Market cap | US$186.20m |
| Earnings (TTM) | -US$344.72m |
| Revenue (TTM) | US$199.87m |
0.9x
P/S Ratio-0.5x
P/E RatioIs CGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGC income statement (TTM) | |
|---|---|
| Revenue | CA$276.75m |
| Cost of Revenue | CA$192.61m |
| Gross Profit | CA$84.14m |
| Other Expenses | CA$561.45m |
| Earnings | -CA$477.31m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 30, 2025
| Earnings per share (EPS) | -3.02 |
| Gross Margin | 30.40% |
| Net Profit Margin | -172.47% |
| Debt/Equity Ratio | 74.7% |
How did CGC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 09:06 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Canopy Growth Corporation is covered by 25 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Gaurav Jain | Barclays |